Posted by Michael Wonder on 28 May 2020
Tax payers paid to develop remdesivir but will have no say when Gilead sets the price
27 May 2020 - Critics say government deserves more credit for tens of millions in public money spent to develop coronavirus treatment.
The drug that buoyed expectations for a coronavirus treatment and drew international attention for Gilead Sciences, remdesivir, started as a reject, an also-ran in the search for antiviral drugs.
Its path to relevance didn’t begin until Robert Jordan plucked it from mothballs.
